In addition, the ATR inhibitor AZD6738 combined with radiotherapy (NCT02223923) is currently being studied in phase I clinical trials for the treatment of patients with advanced solid tumors (including CRC) to evaluate the safety and tolerability of AZD6738 as a single agent or in combination with radiotherapy (Table 3). The gene discussed is ATR; the disease is colorectal carcinoma.